Dicot's business concept is to develop the product Libiguin® as a drug for treating sexual dysfunctions. The development takes place on its own up to clinical phases.

Press release
11 December, 2019

Correction: Dicot Expands its Management Team

(Earlier today, December 11, 2019, a press release was incorrectly published citing the Market Abuse Regulation (MAR). The information in the press release is regulatory but not of a MAR nature). Jessica Roxhed joins Dicot as CFO, Julie Silber's role...

Press release
11 December, 2019

Dicot Expands its Management Team

Jessica Roxhed joins Dicot as CFO, Julie Silber's role as Director of Investor Relations expands and Gabriela Urquilla will head up external communications, reporting to the Director of IR, effective December 15, 2019.

Press release
26 November, 2019

Correction: Dicot nomination committee appointed for AGM 2020

(The previous press release was sent out at 08:00 CET and has been updated to correct a spelling error. Nothing else differs from the previous press release.) November 26, 2019, Uppsala, Sweden - Dicot AB (publ) ("Dicot" or the "Company") The Nominat...

"Lust and joy for life"

With the motto "Lust and joy for life," the company's strategy is to develop Libiguin® up to clinical phase II, after which the company plans to partner with a major pharmaceutical company to be able to take Libiguin® to registered drug distintion and introduce Libiguin® to the global market.

The goal is Libiguin® to become the first-choice treatment for the treatment of erectile dysfunction (ED) and premature ejaculation (PE) and to take a predominant market share for the treatment of patients in those indications.

Watch CEO Göran Beijer presenting the company:

Contact us

Dicot AB
Dag Hammarskjölds Väg 30
SE-752 37 Uppsala SWEDEN
+46 (0) 70-663 60 09
info@dicot.se

The information is processed according to our privacy policy.